Respiratory Syncytial Virus

Disease State Hub

Quizzes

3-in-30

3-in-30

Fall 2025 COVID-19 Vaccine Guidance Quiz for Clinicians: ACIP Updates, Coadministration, and Access

10/29/2015

Anthony Calabro, MA

Test your knowledge of the latest Advisory Committee on Immunization Practices guidance, vaccine coadministration with influenza and respiratory syncytial virus shots, and state-level access changes. Three...

10/29/2015

Respiratory Syncytial Virus Snapshot

For more viral infections content, visit the Disease State Hub

Respiratory syncytial virus (RSV) is a common respiratory virus that typically causes mild symptoms, similar to a cold. Most people recover within 1 to 2 weeks, but it can be serious for infants and older adults.

For pulmonary disorders content, visit the Disease State Hub

Pulmonologists, Infectious Disease Specialists, Primary Care, Pediatricians, Geriatricians

People show symptoms within 4 to 6 days after infection, and symptoms typically appear in stages, rather than all at once.

Symptoms include: rhinorrhea (runny nose), decrease in appetite, coughing, sneezing, fever, and wheezing

For diagnosis strategies content, visit the Resource Center

Testing is not typically required, as the symptoms are similar to a cold. A physician may run tests, such as a mouth swab or blood test to check white blood cell count and the presence of viruses.

For public health content, visit the Resource Center

Globally, RSV affects 64 million people each year and causes 160,000 deaths annually. The virus is the most common cause of bronchiolitis (inflammation in the small airways of a person's lungs).

For critical care content, visit the Resource Center

RSV sends approximately 58,000 children aged 5 years or younger to hospitals for treatment every year. For the same population, 100 to 300 deaths can occur each year due to RSV. *United States data

For intensive care medicine content, visit the Resource Center

RSV in older adults results in 60,000 to 160,000 hospitalizations each year and approximately 6,000 to 10,000 adults aged 65 years or older die from the virus. *United States data

Research Summaries

Respiratory Diseases Roundup

Respiratory Diseases Roundup

SARS-CoV-2 and RSV Cardiopulmonary Risk Updates

04/06/2026

Kate Young

New reports link SARS-CoV-2 and RSV to persistent cardiopulmonary risk and describe distinct postviral lung and brain changes in a mouse model.

04/06/2026

Respiratory Diseases Roundup

Respiratory Diseases Roundup

The Latest in COVID-19 News: Vaccine Effectiveness, 4-in-1 Home Test, Metformin and Long COVID

04/03/2026

Kate Young

This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.

04/03/2026

Research Summary

RSV Prefusion F Vaccine Significantly Reduces RSV-Related Hospitalizations in Older Adults in Denmark

02/09/2026

Ashton L. Stahl

A large pragmatic randomized trial evaluated whether a bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine could reduce RSV-related hospitalizations among adults aged 60 years or...

02/09/2026

Respiratory Diseases Roundup

Respiratory Diseases Roundup

Emerging Data on Durability, Immunogenicity, and Patient Trust

01/05/2026

Kate Young

New data describe durability of XBB.1.5 vaccine antibodies, platform-specific vaccine immunogenicity, CDC safety trust, and 2025 US uptake barriers.

01/05/2026

Research Summary

Research Summary

Bivalent RSV Vaccine Lowers Cardiorespiratory Hospitalizations in Older Adults

11/19/2025

Kate Young

In a nationwide Danish trial of more than 130,000 adults aged 60 years and older, a single dose of the bivalent RSV prefusion F protein vaccine reduced all-cause cardiorespiratory hospitalizations by nearly...

11/19/2025

April 2026

Current Issue

April 2026

Sources: